[1]韩少静,郭永泽,郑 扬,等.内镜下胃癌活检组织中组织蛋白酶D和人类表皮生长因子受体2表达及意义[J].陕西医学杂志,2023,52(9):1249-1253.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.032]
　HAN Shaojing,GUO Yongze,ZHENG Yang,et al.Expression and significance of cathepsin D and human epidermal growth factor receptor 2 in endoscopic gastric cancer biopsy[J].,2023,52(9):1249-1253.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.032]
点击复制

内镜下胃癌活检组织中组织蛋白酶D和人类表皮生长因子受体2表达及意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年9期
页码:
1249-1253
栏目:
临床病理
出版日期:
2023-09-05

文章信息/Info

Title:
Expression and significance of cathepsin D and human epidermal growth factor receptor 2 in endoscopic gastric cancer biopsy
作者:
韩少静1; 郭永泽2; 郑 扬1; 陈旭峰1; 宗 静1; 向正国1
(1.解放军联勤保障部队第九〇四医院消化内科,江苏 无锡 214101; 2.河北工程大学附属医院消化内科,河北 邯郸 056008)
Author(s):
HAN Shaojing; GUO Yongze; ZHENG Yang; CHEN Xufeng; ZONG Jing; XIANG Zhengguo
(Department of Gastroenterology,the 904 Hospital of the Joint Service Support Force of PLA,Wuxi 214101,China)
关键词:
胃癌;  组织蛋白酶D;  人类表皮生长因子受体2;  临床病理特征;  预后
Keywords:
Gastric cancer;  Cathepsin D;  Human epidermal growth factor receptor 2;  Clinicopathological characteristics;  Prognosis
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7377.2023.09.032
文献标志码:
A
摘要:
目的:探讨内镜下胃癌活检组织中组织蛋白酶D(CTSD)和人类表皮生长因子受体2(HER2)表达及意义。方法:选取行内镜活检的胃癌患者81例为研究对象。通过免疫组化法检测胃癌活检组织中CTSD、HER2的表达,并进行随访。分析两者表达与胃癌患者临床病理特征的关系。绘制Kaplan-Meier曲线分析两者表达与胃癌患者预后的关系; 采用Cox比例风险回归模型分析胃癌患者预后的影响因素。结果:CTSD和HER2在胃癌活检组织中阳性表达率分别为46.91%、20.99%。CTSD表达与胃癌分化程度、淋巴结转移及临床分期有关(均P<0.05)。HER2表达与胃癌分化程度、Lauren分型、淋巴结转移及临床分期有关(均P<0.05)。CTSD表达阳性患者5年生存率低于CTSD表达阴性患者5年生存率(26.32%与55.81%,P<0.05)。HER2表达阳性患者5年生存率与阴性患者比较,差异无统计学意义(29.41%与45.31%,P>0.05)。Lauren分型、HP感染、淋巴结转移、临床分期及CTSD表达为胃癌患者预后的独立影响因素(均P<0.05)。结论:胃癌活检组织中CTSD和HER2的表达与胃癌分化程度、淋巴结转移等临床病理特征相关,且CTSD表达可作为胃癌患者预后的独立影响因素。
Abstract:
Objective:To investigate the expression and significance of cathepsin D(CTSD)and human epidermal growth factor receptor 2(HER2)in endoscopic gastric cancer biopsy.Methods:A total of 81 patients with gastric cancer who underwent endoscopic biopsy were selected as subjects.The expressions of CTSD and HER2 in gastric cancer biopsy tissues were detected by immunohistochemistry and followed up.The relationship between their expression and clinicopathologic features in patients with gastric cancer was analyzed.Kaplan-Meier curve was drawn to analyze the relationship between their expression and prognosis in patients with gastric cancer.Cox proportional risk regression model was used to analyze the prognostic factors of patients with gastric cancer.Results:The positive expression rates of CTSD and HER2 in gastric cancer biopsy were 46.91% and 20.99%,respectively.The expression of CTSD was correlated with the differentiation degree,lymph node metastasis and clinical stage of gastric cancer(all P<0.05).The expression of HER2 was correlated with the differentiation degree of gastric cancer,Lauren's classification,lymph node metastasis and clinical stage(all P<0.05).The 5-year survival rate of patients with positive CTSD expression was lower than that of patients with negative CTSD expression(26.32% vs.55.81%,P<0.05).There was no significant difference in 5-year survival rate between HER2-positive patients and negative patients(29.41% vs.45.31%,P>0.05).Lauren's classification,HP infection,lymph node metastasis,clinical stage and CTSD expression were independent factors influencing the prognosis of gastric cancer patients(all P<0.05).Conclusion:The expression of CTSD and HER2 in gastric cancer biopsy tissues is correlated with the degree of differentiation of gastric cancer,lymph node metastasis and other clinicopathologic features,and CTSD expression can be an independent prognostic factor for patients with gastric cancer.

参考文献/References:

[1] 吴 丹,曹 司,黄 坤.CDX2、HNF4α、SOX2蛋白联合检测对幽门螺杆菌感染相关高危胃癌的诊断价值[J].中南医学科学杂志,2021,49(6):695-698.
[2] 张晓昉.胃癌原发灶活检标本与淋巴结转移内HER2状态及临床病理相关性分析[J].实用癌症杂志,2019,34(2):257-260.
[3] Zhou C,Hu J,Wang Y,et al.A machine learning-based predictor for the identification of the recurrence of patients with gastric cancer after operation[J].Sci Rep,2021,11(1):1571.
[4] Liu CM,Shen HT,Lin YA,et al.Antiproliferative and antimetastatic effects of praeruptorin C on human non-small cell lung cancer through inactivating ERK/CTSD signalling pathways[J].Molecules,2020,25(7):1625.
[5] 张 磊.胃癌内镜下活检组织中Vav1、CTSD表达量与临床生物学行为的相关性[J].海南医学院学报,2018,24(11):1106-1108,1112.
[6] Peckys DB,Hirsch D,Gaiser T,et al.Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue[J].Mol Med,2019,25(1):42.
[7] 缪亚军,张 亮,杨 莉,等.CA199、CA125与HER2与胃癌患者预后的关系[J].现代消化及介入诊疗,2020,25(9):1200-1203.
[8] 贾鑑慧.常见消化系肿瘤诊治学[M].沈阳:辽宁科学技术出版社,2014:26-27.
[9] 李向阳,任 磊,梁 瑞.血清基质金属蛋白酶-9、基质金属蛋白酶-2水平对胃癌腹膜转移及预后的预测价值[J].陕西医学杂志,2023,52(2):166-170.
[10] 王 洁,张云清,赵 斌,等.K-ras诱导细胞衰老与胃癌及癌前病变关系研究[J].陕西医学杂志,2021,50(3):370-373.
[11] 杨敬端,何 明,吴 品.胃癌患者CyPJ、ERp29及CSN5的表达及其与预后生存的关系研究[J].分子诊断与治疗杂志,2021,13(3):478-482.
[12] 王诗妍,林 晚,张飞雄.AMPK、YAP1与E-cadherin蛋白在胃癌组织中的表达及临床意义[J].宁夏医科大学学报,2021,43(11):1141-1145,1150.
[13] 袁海涛,周晓东,张 垚,等.环状RNA has_circ_0079557在胃癌中的表达及其临床意义[J].江苏大学学报:医学版,2021,31(6):461-466.
[14] 高聪聪,范 筱,李 宁.益气健脾化积方对胃癌化疗疗效、患者安全性及预后影响的研究[J].陕西中医,2019,40(4):475-477.
[15] 张至惠,李 沐.附子理中汤加减对脾肾阳虚型胃癌术后化疗患者血清肿瘤标志物的影响[J].陕西中医,2019,40(2):171-173,177.
[16] 李 扬,彭 巍,钟进才.伊尼妥单抗联合吡咯替尼二线治疗HER2阳性患者1例[J].中国新药杂志,2023,32(9):916-920.
[17] Baig MMFA,Lai WF,Mikrani R,et al.Synthetic NRG-1 functionalized DNA nanospindels towards HER2/neu targets for in vitro anti-cancer activity assessment against breast cancer MCF-7 cells[J].J Pharm Biomed Anal,2020,182:113133.
[18] Normann LS,Aure MR,Leivonen SK,et al.MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro[J].Sci Rep,2021,11(1):10893.
[19] Mangiapane LR,Nicotra A,Turdo A,et al.PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells[J].Gu,2022,71(1):119-128.
[20] Velaga R,Tanaka S,Toi M.Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours[J].Cancer Drug Resist,2022,5(2):487-497.

相似文献/References:

[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
　HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(9):121.
[2]唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究*[J].陕西医学杂志,2019,(4):435.
　TANG Yarong..Clinical effect analysis of combined therapy with tiago and hyperthermia in the treatment of malignant ascites in elderly patients with gastric cancer[J].,2019,(9):435.
[3]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
　LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(9):456.
[4]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[5]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
　MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(9):679.
[6]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
　SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(9):958.
[7]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010.
　GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(9):1010.
[8]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
　KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(9):1115.
[9]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[10]刘维帅,郭晓宁,杨 洋,等.胃癌病理类型及临床预后与血清miR-133a和DKK-1相关性分析[J].陕西医学杂志,2020,49(6):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
　LIU Weishuai,GUO Xiaoning,YANG Yang,et al.Correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1[J].,2020,49(9):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]

备注/Memo

备注/Memo:
基金项目:河北省科学技术厅资助项目(202130821010208)
更新日期/Last Update: 2023-09-04